A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " TRANS GENIC INC.

TRANS GENIC INC.

Table of Contents

TRANS GENIC INC. is a company whose strengths include a 40-year history, a proven track record, and technologies developed at GLP-compliant facilities. This section details the features of TRANS GENIC INC.’s nonclinical studies, provides an example of a disease model, and presents case studies. Please use this information as a reference when selecting a contract research company.

Characteristics of TRANS GENIC INC. Non-Clinical Contract Services

Use of Genetically Engineered (TRANS GENIC INC.) Animal Models

Specializes in non-clinical studies using genetically engineered mice and ratsTRANS GENIC INC. is a company whose strengths include a 40-year history, a proven track record, and technologies developed at GLP-compliant facilities. This section details the features of TRANS GENIC INC.’s nonclinical studies, provides an example of a disease model, and presents case studies. Please use this information as a reference when selecting a contract research company.

Providing Diverse Disease Models

TRANS GENIC INC.offers models covering a broad range of disease areas, including the central nervous system, the cardiovascular system, and metabolic diseases, to address varied research needs.

Seamless Support System

A system is in place to support a smooth transition from nonclinical to clinical trial phases, enabling the collection and use of data from early development to advance to subsequent steps efficiently.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models Available at TRANS GENIC INC.

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

Parkinson’s Disease Model (mouse)

Mice are used as animal models that exhibit key pathological features of Parkinson’s disease. This disease model is expected to support elucidation of Parkinson’s disease mechanisms and the development of new treatment approaches.

Cerebral Infarction (Stroke) Model (rat)

The company maintains a rat model of cerebral infarction to facilitate the development of new treatment methods. This disease model enables evaluation of the effects of therapies and rehabilitation on a range of symptoms caused by cerebral infarction.

TRANS GENIC INC. Non-clinical Case Studies

No case studies are currently listed on the official website.

TRANS GENIC INC. Corporate Information

TRANS GENIC INC. operates a drug discovery support business as well as an investment and consulting business. In drug discovery support, the company provides services spanning from the early stages of discovery through the clinical trial stage, including the creation of genetically engineered animals, nonclinical testing, and antibody production. In its investment and consulting business, the company supports clients through M&A and business restructuring.

Address	2-3-36 Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka, Japan
Tel	092-288-8470
Website	https://www.transgenic.co.jp/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us